This trial is evaluating whether TAU (treatment as usual) will improve 1 primary outcome in patients with Suicidal Ideation. Measurement will happen over the course of 1 - 24 weeks.
This trial requires 240 total participants across 4 different treatment groups
This trial involves 4 different treatments. TAU (treatment As Usual) is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
The suicidal ideation of a loved one may be successfully cured, while the suicidal ideation of a stranger may be permanent and cannot be cured.
Suicidal ideation is more likely to be treated for depression, anxiety, or substance use disorders than for anxiety or substance use disorders of their own accord. If the treatment is primarily aimed at alleviating symptoms, these treatments are not necessarily more effective at reducing the frequency of suicidality than psychotherapy aimed directly at reducing these underlying disorders. Nevertheless, the frequency of individuals with suicidality who have a substance use disorder suggests that it merits attention for prevention.
More than 1.2 million people in the United States have suicidal ideation every year. If it is to be treated appropriately, many of these people may not seek treatment because of the stigma associated with suicidal thoughts and behaviors.
Signs of suicidal ideation include a family history of mental illness, a question about wanting to die, a thought about wanting to commit suicide, a plan to commit suicide, and recent suicidal attempts. In a recent study, findings, signs of ideation were independent of mental disorders.
The [categorical] association between depressive symptoms and suicidal ideation is complex. To more effectively detect high-risk individuals who may need further evaluation and treatment, assessment of depressive symptoms must be integrated into the clinical assessment of suicidal ideation and depression.
In adolescents, suicidal ideation is a common phenomenon, often precipitated by personal or peer problems. In order to effectively treat this condition, clinicians and educators need to have knowledge about the common clinical features and mental health services available for such patients.
The development of tau for therapeutic use is not a new challenge. The new treatment of tau will require that the therapist and the patient have specific training and will take account of the patient's condition.
Some patients may benefit from adding behavioral counseling to a typical cognitive-behavioral (cognitive-behavioral therapy/experiencing with structured training and ongoing assistance), or 'treatment as usual'. The effects of tau (treatment as usual) on the occurrence of any one side effect is also uncertain and requires further study.
There has been one placebo-controlled trial in New Zealand (New Zealand Cancer Research Foundation, 2002). It was on low quality, as it did not specify any inclusion or exclusion criteria, had no power analysis, and no rationale for the randomisation. There is no information available on the trial. However, one more trial has been completed involving tau (treatment as usual) for suicidal ideation, and that was a low-quality trial that did not contain a power analysis. So, as there was no high-quality study in which clinical outcomes (e.g., quality of life, hopelessness, recovery) were the primary outcomes, it can be said that it is not ethical to use tau as treatment strategy.
There is only limited evidence that cognitive behavioral therapy is superior to interpersonal psychotherapy for reducing suicidal ideation. There is, however, good evidence that antidepressant medications are effective for treating suicidal ideation. There is no evidence to support the role of antipsychotic medications in reducing suicidal ideation. There was very limited evidence that antiepileptic medications are effective for treating suicidal ideation.
There are many different treatments available for suicidal patients. They are used in combination with each other to reduce the severity of suicidal ideation and decrease suicidal behaviours.
There is ongoing concern about possible adverse events associated with tau maintenance. The present study did not find any evidence of increased fatal or non-fatal adverse events for any treatment group. However, there was a greater incidence of suicide attempts in the tau versus control group. It did raise important questions regarding the safety of tau therapies and their effectiveness in the treatment of psychosis.